Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
68.56
-3.34 (-4.65%)
Mar 26, 2025, 4:00 PM EST - Market closed

Company Description

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD).

The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV being developed for the prevention of IPD in adults and children.

VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI to prevent dysentery and shigellosis.

The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020.

Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Vaxcyte, Inc.
Vaxcyte logo
Country United States
Founded 2013
IPO Date Jun 12, 2020
Industry Biotechnology
Sector Healthcare
Employees 414
CEO Grant Pickering

Contact Details

Address:
825 Industrial Road, Suite 300
San Carlos, California 94070
United States
Phone 650 837 0111
Website vaxcyte.com

Stock Details

Ticker Symbol PCVX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001649094
CUSIP Number 92243G108
ISIN Number US92243G1085
Employer ID 46-4233385
SIC Code 2836

Key Executives

Name Position
Grant E. Pickering M.B.A. Co-Founder, Chief Executive Officer and Director
Andrew L. Guggenhime M.B.A. President and Chief Financial Officer
James Wassil M.B.A., M.S. Executive Vice President and Chief Operating Officer
Mikhail Eydelman J.D. Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
Dr. Jeff Fairman Ph.D. Co-Founder and Vice President of Research
Janet Graesser Senior Vice President of Corporate Communications and Investor Relations
Whitney Jones Chief People Officer
Paul W. Sauer M.B.A. Senior Vice President of Process Development and Manufacturing
Harp Dhaliwal M.B.A. Chief Technical Operations Officer
Sam Iki Senior Vice President of Project Management

Latest SEC Filings

Date Type Title
Mar 5, 2025 144 Filing
Mar 3, 2025 144 Filing
Feb 25, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 25, 2025 10-K Annual Report
Feb 25, 2025 8-K Current Report
Feb 18, 2025 144 Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 12, 2025 SCHEDULE 13G/A Filing
Feb 5, 2025 144 Filing
Feb 3, 2025 144 Filing